Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in china

HIGHLIGHTS

• who: Huiqin Liu from the Department of Medical Insurance, Cancer Prevention and Treatment Medical College, Affiliated Fifth Peopleu2019s Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, China have published the research work: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China, in the Journal: (JOURNAL)
• what: The aim of this study was to evaluate the cost efectiveness of sintilimab plus chemotherapy versus Platinum-based chemotherapy for locally advanced or metastatic squamous NSCLC in China. Treatment costs . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.